Year All2026202520242023 Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility June 10, 2026 PDF Version Read More Incannex Announces Initiation of Research Coverage by Alliance Global Partners June 9, 2026 PDF Version Read More Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea May 14, 2026 PDF Version Read More Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development May 12, 2026 PDF Version Read More Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness April 22, 2026 PDF Version Read More Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position March 27, 2026 PDF Version Read More Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research March 25, 2026 PDF Version Read More Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development March 18, 2026 PDF Version Read More Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement March 17, 2026 PDF Version Read More Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules March 12, 2026 PDF Version Read More ASX Announcements
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility June 10, 2026 PDF Version Read More
Incannex Announces Initiation of Research Coverage by Alliance Global Partners June 9, 2026 PDF Version Read More
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea May 14, 2026 PDF Version Read More
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development May 12, 2026 PDF Version Read More
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness April 22, 2026 PDF Version Read More
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position March 27, 2026 PDF Version Read More
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research March 25, 2026 PDF Version Read More
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development March 18, 2026 PDF Version Read More
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement March 17, 2026 PDF Version Read More
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules March 12, 2026 PDF Version Read More
